Jaguar Health, Inc.（JAGX）及其子公司Napo Pharmaceuticals，与Alivus Therapeutics于2026年7月9日共同签署了一项关于Crofelemer（一种用于治疗多种腹泻适应症的植物源性药物）的新制造与供应协议。该协议已根据美国证券交易委员会（SEC）的相关规定提交文件。
根据协议条款，三方将深化在Crofelemer原料药及成品制剂的生产与供应方面的合作关系。此举旨在优化供应链稳定性、确保产品质量一致性，并支持该药物在全球现有及潜在市场的商业化拓展。协议预计将提升Jaguar Health旗下相关产品的长期供应保障能力，并可能对公司的成本结构及未来营收产生积极影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.